FDA Approves Genentech Medicine for Women with Advanced Cervical Cancer
August 14th, 2014
On August 14, 2014, the FDA approved Avastin® (bevacizumab) in combination with paclitaxel and cisplatin or paclitaxel and topotecan for the treatment of women with persistent, recurrent or metastatic carcinoma of the cervix.
News in brief
- Women with advanced cervical cancer now have the option of Avastin plus chemotherapy to help them live longer than with chemotherapy alone.
- Prior to this approval, chemotherapy was the only approved treatment option for women whose cancer recurred, persisted or spread.
- Avastin is approved in the United States to treat five distinct tumor types.
Supporting Information
“With this approval, women with advanced cervical cancer now have the option of Avastin plus chemotherapy to help them live longer than with chemotherapy alone. Cervical cancer is most commonly diagnosed in women between the ages of 35 and 44, and until today, chemotherapy was the only approved treatment option for women whose cancer recurred, persisted or spread.”